|
Form Serial Number: |
DA20240517E00428
|
1.
Date of relevant event: |
13/05/2024 (dd/mm/yyyy)
|
2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
(dd/mm/yyyy)
|
3.
Stock code: |
01513 |
4.
Name of listed corporation: |
丽珠医药集团股份有限公司 - H股 |
5.
Class of shares: |
A Shares |
6.
Number of issued shares in class: |
618,628,742 |
7.
Name of director (English) as printed on HKID Card/Passport: |
(Surname) |
XU |
(Other names) |
GUOXIANG |
|
|
|
10.
Name of director (Chinese): |
徐国祥 |
11.
Chinese Character Code as printed on HKID Card: |
|
|
24.
Details of relevant event: |
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
Long position |
12041 | The number of shares in which you are interested has reduced because: expiry or cancellation without exercise of equity derivatives under which (choose one): you had a right to take the underlying shares | |
|
|
48,000 |
CNY |
31.3100 |
31.3100 |
|
|
Short position |
|
|
|
|
|
|
|
|
|
|
|
25.
Total shares in listed corporation immediately before the relevant event: |
| Total number of shares | Percentage figure (%) |
Long position | 943,800 | 0.15 |
|
|
26.
Total shares in listed corporation immediately after the relevant event: |
| Total number of shares | Percentage figure (%) |
Long position | 895,800 | 0.14 |
|
|
27.
Capacity in which interests disclosed in Box 26 are held: |
Code describing capacity | Number of shares |
| |
| |
|
|
28.
Further information in derivative interests in listed corporation : |
Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
Long position | 4105 | Unlisted derivatives - Physically settled |
| 23/11/2023 | 22/11/2024 | CNY | 0 | CNY | 31.310 | | | 64,000 |
Long position | 4105 | Unlisted derivatives - Physically settled |
| 23/11/2024 | 22/11/2025 | CNY | 0 | CNY | 31.310 | | | 0 |
Long position | 4105 | Unlisted derivatives - Physically settled |
| 23/11/2025 | 22/11/2026 | CNY | 0 | CNY | 31.310 | | | 48,000 |
|
|
29.
Further information in relation to interests of children under 18 and/or spouse: |
Child/Spouse | Name of child/spouse | Number of shares |
| | |
|
|
30.
Further information in relation to interests of corporations controlled by Director: |
Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| | | | | |
|
|
31.
Further information in relation to interests held by Director jointly with another person: |
Name of joint shareholder | Address | Number of shares |
| | |
|
|
32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
Names of Trust | Address | Status code | Number of shares |
| | | |
|
|
33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
Names of other parties | Address | Number of shares |
| | |
Total number of shares in which a director is interested under sections 317 and 318 | |
|
|
34.
Supplementary information: |
根據麗珠醫藥集團股份有限公司(“本公司”)2022年股票期權激勵計劃的相關規定及《2023年年度審計報告》,本公司首次授予股票期權第二個行權期及預留授予股票期權第一個行權期對應本公司層面業績考核目標不達標,因此,首次授予股票期權第二個行權期對應的股票期權528.375萬份和預留授予股票期權第一個行權期對應的股票期權100.00萬份不得行權,由本公司註銷。因此,本公司董事徐國祥持有的首次授予股票期權第二個行權期的4.8萬份股票期權予以註銷。
|
35.
Log/Serial Number of the previous form: |
|
36.
Number of concert party document(s) under section 317 attached/uploaded: |
|
Date of filing this Form 3A: |
17/05/2024 (dd/mm/yyyy)
|
|